CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Novo Nisk Adr Repsg 1 - NVO CFD

122.62
0.02%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.19
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Novo Nordisk A/S ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 122.64
Open* 123.53
1-Year Change* -27.19%
Day's Range* 122.5 - 124.27
52 wk Range 65.59-108.98
Average Volume (10 days) 4.22M
Average Volume (3 months) 82.99M
Market Cap 367.07B
P/E Ratio 44.25
Shares Outstanding 4.52B
Revenue 31.29B
EPS 2.43
Dividend (Yield %) 0.47813
Beta 0.41
Next Earnings Date Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 122.62 -0.73 -0.59% 123.35 124.46 122.29
Apr 18, 2024 122.64 -0.64 -0.52% 123.28 124.02 122.45
Apr 17, 2024 124.45 -0.44 -0.35% 124.89 125.12 123.15
Apr 16, 2024 123.35 0.40 0.33% 122.95 124.17 121.69
Apr 15, 2024 123.65 -2.03 -1.62% 125.68 125.98 123.43
Apr 12, 2024 124.43 -2.19 -1.73% 126.62 126.98 124.22
Apr 11, 2024 125.27 -0.26 -0.21% 125.53 125.71 124.08
Apr 10, 2024 124.85 1.56 1.27% 123.29 125.19 123.22
Apr 9, 2024 124.78 -1.24 -0.98% 126.02 126.64 124.13
Apr 8, 2024 127.40 0.47 0.37% 126.93 127.51 125.92
Apr 5, 2024 125.56 0.99 0.79% 124.57 126.09 124.50
Apr 4, 2024 123.82 -2.96 -2.33% 126.78 127.39 123.50
Apr 3, 2024 126.92 1.54 1.23% 125.38 128.05 125.28
Apr 2, 2024 126.37 1.67 1.34% 124.70 126.61 124.02
Apr 1, 2024 127.47 -1.49 -1.16% 128.96 128.96 127.07
Mar 28, 2024 128.33 0.01 0.01% 128.32 130.07 127.61
Mar 27, 2024 127.99 -0.32 -0.25% 128.31 128.57 127.22
Mar 26, 2024 129.32 -0.54 -0.42% 129.86 129.91 128.35
Mar 25, 2024 128.98 0.12 0.09% 128.86 130.17 128.63
Mar 22, 2024 128.68 -0.39 -0.30% 129.07 129.36 128.05

Novo Nisk Adr Repsg 1 Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 176954 140800 126946 122021 111831
Revenue 176954 140800 126946 122021 111831
Cost of Revenue, Total 28448 23658 20932 19559 17617
Gross Profit 148506 117142 106014 102462 94214
Total Operating Expense 102145 82156 72820 69538 64583
Selling/General/Admin. Expenses, Total 49932 40409 36108 35301 33656
Research & Development 21761 16292 13713 13477 13568
Depreciation / Amortization 2478 1631 2178 856 1289
Unusual Expense (Income) 809 714 477 1200 -6
Other Operating Expenses, Total -1283 -548 -588 -855 -1541
Operating Income 74809 58644 54126 52483 47248
Interest Income (Expense), Net Non-Operating -5566 558 -846 -3757 439
Other, Net -181 -122 -150 -173 -72
Net Income Before Taxes 69062 59080 53130 48553 47615
Net Income After Taxes 55525 47757 42138 38951 38628
Net Income Before Extra. Items 55525 47757 42138 38951 38628
Net Income 55525 47757 42138 38951 38628
Income Available to Common Excl. Extra. Items 55525 47757 42138 38951 38628
Income Available to Common Incl. Extra. Items 55525 47757 42138 38951 38628
Dilution Adjustment
Diluted Net Income 55525 47757 42138 38951 38628
Diluted Weighted Average Shares 4544.6 4606.2 4680 4757.32 4848.83
Diluted EPS Excluding Extraordinary Items 12.2178 10.368 9.00385 8.1876 7.96645
Dividends per Share - Common Stock Primary Issue 5.55799 4.81518 3.96122 4.07135 4.1288
Diluted Normalized EPS 12.3609 10.4933 9.08468 8.38996 7.96545
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 54300 53367 48092 45566 41265
Revenue 54300 53367 48092 45566 41265
Cost of Revenue, Total 7856 8182 8262 7200 6069
Gross Profit 46444 45185 39830 38366 35196
Total Operating Expense 30412 28360 31005 25382 22874
Selling/General/Admin. Expenses, Total 15414 13483 15091 12609 11831
Research & Development 7127 6728 8085 5633 5123
Other Operating Expenses, Total 15 -33 -433 -60 -149
Operating Income 23888 25007 17087 20184 18391
Interest Income (Expense), Net Non-Operating 366 -270 -771 -2152 -1596
Net Income Before Taxes 24254 24737 16316 18032 16795
Net Income After Taxes 19428 19814 13592 14405 13318
Net Income Before Extra. Items 19428 19814 13592 14405 13318
Net Income 19428 19814 13592 14405 13318
Income Available to Common Excl. Extra. Items 19428 19814 13592 14405 13318
Income Available to Common Incl. Extra. Items 19428 19814 13592 14405 13318
Diluted Net Income 19428 19814 13592 14405 13318
Diluted Weighted Average Shares 4502.6 4513.2 4608.8 4537 4552.2
Diluted EPS Excluding Extraordinary Items 4.31484 4.39023 2.94914 3.17501 2.92562
Dividends per Share - Common Stock Primary Issue 4.0269 0 2.00676 0 3.62596
Diluted Normalized EPS 4.31484 4.39023 2.94914 3.17501 2.92562
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 108194 85595 65809 62456 59067
Cash and Short Term Investments 23116 16362 12104 14966 15638
Cash 12195 9597 12104 14966 15638
Short Term Investments 10921 6765
Total Receivables, Net 57505 46799 32184 29152 24836
Accounts Receivable - Trade, Net 50560 40643 27734 24912 22786
Total Inventory 24388 19621 18536 17641 16336
Prepaid Expenses 2053
Other Current Assets, Total 3185 2813 2985 697 204
Total Assets 241257 194508 144922 125612 110769
Property/Plant/Equipment, Total - Net 66671 55362 50269 50551 41891
Property/Plant/Equipment, Total - Gross 111426 95887 86686 84420 72438
Accumulated Depreciation, Total -44755 -40525 -36417 -33869 -30547
Intangibles, Net 46324 38825 20657 5835 5145
Long Term Investments 886 1078 1348 1444 1296
Note Receivable - Long Term 663 630 974 1205 477
Other Long Term Assets, Total 13427 8672 5865 4121 2893
Total Current Liabilities 120940 99516 70273 58983 54164
Accounts Payable 15587 8870 5717 6358 6756
Accrued Expenses 875 590 598 478 7015
Notes Payable/Short Term Debt 480 12862 6684 659 515
Other Current Liabilities, Total 103012 76372 56499 50673 39878
Total Liabilities 157771 123762 81597 68019 58930
Total Long Term Debt 24318 12961 2897 3009 0
Deferred Income Tax 4685 5271 2502 80 118
Other Liabilities, Total 7828 6014 5925 5947 4648
Total Equity 83486 70746 63325 57593 51839
Common Stock 456 462 470 480 490
Retained Earnings (Accumulated Deficit) 80625 72934 63589 58291 54102
Treasury Stock - Common -6 -6 -8 -10 -11
Other Equity, Total 2411 -2644 -726 -1168 -2742
Total Liabilities & Shareholders’ Equity 241257 194508 144922 125612 110769
Total Common Shares Outstanding 3962.8 4015.07 4088 4167 4251
Current Port. of LT Debt/Capital Leases 986 822 775 815
Capital Lease Obligations 3543 3307 2897 3009
Goodwill, Net 5092 4346
Long Term Debt 20775 9654
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 142199 137551 113943 108194 119482
Cash and Short Term Investments 47595 36408 27771 23574 37473
Cash 30144 21574 14936 12653 28465
Short Term Investments 17451 14834 12835 10921 9008
Total Receivables, Net 61964 70521 57921 57505 53510
Accounts Receivable - Trade, Net 52602 61294 50502 50560 45563
Total Inventory 29534 28020 25615 24388 23222
Other Current Assets, Total 3106 2602 2636 2727 5277
Total Assets 300101 280753 250025 241257 242836
Property/Plant/Equipment, Total - Net 81461 75024 70014 66671 63641
Intangibles, Net 55726 50749 50489 51416 46924
Long Term Investments 1471 1479 1211 1343 1239
Note Receivable - Long Term 430 338 288 206 247
Other Long Term Assets, Total 18814 15612 14080 13427 11303
Total Current Liabilities 172552 156618 131961 120940 130257
Accounts Payable 20106 17788 10050 15587 8310
Notes Payable/Short Term Debt 0 0 0 480 0
Current Port. of LT Debt/Capital Leases 6613 6289 1251 986 1833
Other Current Liabilities, Total 145833 132541 120660 103887 120114
Total Liabilities 207110 190280 170151 157771 166156
Total Long Term Debt 19924 19415 24267 24318 24136
Long Term Debt 19924 19415 24267 20775 24136
Deferred Income Tax 7885 7627 7875 7061 5640
Other Liabilities, Total 6749 6620 6048 5452 6123
Total Equity 92991 90473 79874 83486 76680
Common Stock 451 451 456 456 456
Retained Earnings (Accumulated Deficit) 92545 90025 79424 80625 76228
Treasury Stock - Common -5 -3 -6 -6 -4
Total Liabilities & Shareholders’ Equity 300101 280753 250025 241257 242836
Total Common Shares Outstanding 4523.62 3995.22 3960.95 3962.8 3955.07
Capital Lease Obligations 3543
Other Equity, Total 2411
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 55525 47757 42138 38951 38628
Cash From Operating Activities 78887 55000 51951 46782 45028
Cash From Operating Activities 7362 6025 5753 5661 3925
Non-Cash Items 35847 24332 18841 16634 15085
Cash Taxes Paid 14515 14438 10106 10936 9614
Cash Interest Paid 272 261 422 204 89
Changes in Working Capital -19847 -23114 -14781 -14464 -12610
Cash From Investing Activities -24918 -31605 -22436 -11509 -12080
Capital Expenditures -14753 -7385 -22081 -11231 -12410
Other Investing Cash Flow Items, Total -10165 -24220 -355 -278 330
Cash From Financing Activities -51797 -25493 -32244 -35484 -34521
Total Cash Dividends Paid -25303 -21517 -20121 -19409 -19048
Issuance (Retirement) of Stock, Net -24086 -19447 -16855 -15334 -15567
Foreign Exchange Effects -238 591 -456 -7 44
Net Change in Cash 1934 -1507 -3185 -218 -1529
Issuance (Retirement) of Debt, Net -2408 15471 4732 -741 94
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 19814 55525 41933 27528 14210
Cash From Operating Activities 29814 78887 71786 47547 23586
Cash From Operating Activities 1719 7362 5327 3286 1650
Non-Cash Items 25153 35847 39520 18991 11097
Cash Taxes Paid 6679 14515 9928 8229 5260
Cash Interest Paid 165 272 186 120 52
Changes in Working Capital -16872 -19847 -14994 -2258 -3371
Cash From Investing Activities -6647 -24918 -11068 -6107 -1907
Capital Expenditures -4801 -14753 -8580 -4355 -1780
Other Investing Cash Flow Items, Total -1846 -10165 -2488 -1752 -127
Cash From Financing Activities -20621 -51797 -44129 -29566 -19135
Financing Cash Flow Items 3393 2737
Total Cash Dividends Paid -18337 -25303 -25303 -15690 -15690
Issuance (Retirement) of Stock, Net -5199 -24086 -16547 -11927 -4477
Issuance (Retirement) of Debt, Net -478 -2408 -2279 -1949 -1705
Foreign Exchange Effects -263 -238 606 163 -55
Net Change in Cash 2283 1934 17195 12037 2489

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Nordisk ADR Company profile

Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries worldwide. The company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. Operating through two business segments, including diabetes and obesity care, and biopharmaceuticals. The company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The company’s biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk’s insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. With Capital.com you stay in sync with the latest info on the Novo Nordisk (NVO) share price.
Industry: Pharmaceuticals (NEC)

Novo Alle 1
BAGSVAERD
2880
DK

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

XRP/USD

0.54 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,174.45 Price
+0.250% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

65,028.15 Price
+0.260% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading